Top 10 Pharma CEOs In The World
The Top 10 CEOs In The Pharmaceutical Industry >>>
#1. Ian Read, Pfizer
Ian Read began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995 holding positions ranging from CFO of Pfizer Mexico (Pfizer's largest subsidiary in Latin America) to country manager of Brazil. In 1996, he was appointed president of the Pfizer International Pharmaceuticals Group, Latin America / Canada. He assumed the position of Executive Vice President - Europe/Canada in May 2000, added the responsibilities for Africa /Middle East region as of January 2004 and responsibilities for Latin America in March 2006. He was named Vice President of Pfizer in 2001 and promoted to President of Worldwide Pharmaceutical Operations in 2006. In 2010, he became the Chief Executive of Pfizer.
#2. Joseph Jimenez, Novartis
Jimenez earned a bachelor's degree from Stanford University in 1982, and an MBA from University of California, Berkeley in 1984. Jimenez began his career at Clorox before joining ConAgra Foods. He worked at H. J. Heinz Company from 2002 to 2006, and at AstraZeneca from 2002 to 2007. He has also worked for Blackstone Group. Jimenez joined Novartis in 2007, and was named CEO in 2010 by his predecessor and Chairman Daniel Vasella.
#3. Christopher Viehbacher, Sanofi
After beginning his career at PriceWaterhouseCoopers, between 1988-2008 he acquired broad international experience in Europe, in the United States and in Canada with the GlaxoSmithKline (GSK) company. In his last position, Chris Viehbacher was President, Pharmaceutical Operations North America, a member of the board and Co-Chairman of the Portfolio Management Board. As from December 1, 2008, Chris Viehbacher is a sanofi-aventis board member, CEO and a member of the Strategy Committee.
#4. Kenneth Frazier, Merck
Kenneth Carleton Frazieris the first African American to serve as the CEO of a pharmaceutical company. Frazier, graduated from Pennsylvania State University in 1975 with a BA in Political Science, and attended Harvard Law School. Frazier joined Merck in 1992, and became general counsel of the company in 2006. From 2007 to 2010, he served as executive vice president and president of the company's global human health unit. In 2010, he became Merck's president and on January 1, 2011 it’s CEO.
#5. Andrew Witty, GlaxoSmithKline
Witty joined GSK UK in 1985 as a management trainee. He held various positions in the UK, including Director of Pharmacy & Distribution in Glaxo Pharmaceuticals UK, Director of Business Development of Biocompatibles Limited and International Product Manager of Glaxo Holdings PLC. He served as Managing Director of Glaxo South Africa and Area Director of South and East Africa.
He served as a Vice President and General Manager of Marketing of Glaxo Wellcome Inc., a subsidiary of GlaxoSmithKline with responsibility for strategy development, marketing execution and new product positioning. He was appointed President, Pharmaceuticals Europe of GlaxoSmithKline in January 2003and succeeded Dr Jean-Pierre Garnier as CEO following his retirement in May 2008.
#6. Pascal Soriot, AstraZeneca
Pascal Claude Roland Soriot is the Chief Executive of the Anglo-Swedish pharmaceutical multinational company AstraZeneca, and has been since October 2012. He studied Veterinary Medicine at university and later studied at HEC Paris. In April 1986, he joined Roussel Uclaf (formerly France's second largest pharmaceutical company, until bought by Hoechst AG in 1997). In 1996 he became General Manager of Hoechst Marion Roussel in Australia, moving to Tokyo in April 1997
In 2000 he moved to Aventis in America, becoming Chief Operating Officer of Aventis USA in 2002, which became Sanofi Aventis USA in 2004. He joined Roche in 2006. From April 2009 to 2010 he was Chief Executive of the Roche subsidiary Genentech. He rejoined Roche Pharma AG in 2010 as Chief Operating Officer.
On 28 August 2012 he was named as the new Chief Executive of AstraZeneca.
#7. Alex Gorsky, Johnson and Johnson
Alex Gorsky has been the Chief Executive Officer of Johnson & Johnson since April 26, 2012.
Before the appointment to CEO, Gorsky was the worldwide chairman of the medical devices and diagnostics group at Johnson & Johnson, serving in that role since September 2009. Prior to that, Gorsky served as the worldwide chairman of the surgical care group at Johnson & Johnson and as the chairman of the company's pharmaceutical business in Europe, the Middle East and Africa.
#8. John Lechleiter, Eli Lilly & Co
John Lechleiter, has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008. He became chairman of the board of directors on January 1, 2009. Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982. In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England.
In 1988, he became director of development projects management, and in 1991, Lechleiter was named executive director of pharmaceutical product development, and he became vice president in 1993. He was appointed vice president of regulatory affairs in 1994, was named vice president for development and regulatory affairs in 1996, and became senior vice president of pharmaceutical products in 1998.
In 2001, Lechleiter was appointed executive vice president for pharmaceutical products and corporate development. In 2004, he became Lilly’s executive vice president for pharmaceutical operations. And in 2005, he was named president and chief operating officer and joined the board of directors.
#9. Miles White, Abbot Laboratories
White holds two degrees from Stanford University, a bachelor's degree in mechanical engineering and an MBA. White joined Abbott in 1984, serving there in management positions including senior vice president of diagnostic operations and executive vice president. He was elected to the board of directors in April 1998, to chief executive officer in January 1999, and to chairman of the board in April 1999.
#10. Lamberto Andreotti, Bristol-Myers Squibb
Andreotti graduated from Sapienza University of Rome with a degree in engineering and he holds a Master of Science degree from Massachusetts Institute of Technology.
He worked for many pharmaceutical companies, including Farmitalia Carlo Erba, KABI Pharmacia and Pharmacia & Upjohn. In 1998, he joined Bristol-Myers Squibb.He was elected to the Board of Directors in March 2009 and became CEO on May 4, 2010.
Top 10 healthcare innovations for 2019
We take a look at some of the top 10 healthcare innovations which are transforming the sector
The telehealth market is booming. Consumers are leading increasingly busy lifestyles, with up to 60% favouring digitally-led services. Providing clinical care at a distance, increasing accessibility and eradicating potential delays has given patients greater control, boosting patient satisfaction and overall engagement. Such is its exponential growth, The Centers for Medicare and Medicaid Services in the US has recently released its proposed Physician Fee Schedule and Qualified Payment Programme updates for 2019, where telehealth services has been heavily featured, in order to deliver ‘different access points’ for patients.
9. Mobile technology
Consumers have become accustomed to accessing their data through the use of various digital tools, where the use of mobile and tablet health apps has tripled from 13% in 2014 to 48% today. Catering to this growing market, British based start-up Babylon Health is making waves on a global scale. Partnering with the National Health Service (NHS) and private health provider, Bupa, it has also cemented its presence across the flourishing Chinese market, with a membership base exceeding 1.4mn citizens across Europe, Asia and Africa. By partnering with global juggernaut Tencent, Babylon’s artificial intelligence system has enabled both parties to interact directly with users, identify specific illnesses, deliver health status assessments, and triage necessary actions. The mobile app is available to over a billion users and linked to more than 38,000 medical facilities in China alone.
8. Artificial intelligence
Artificial intelligence (AI) applications, such as predictive analytics for patient monitoring has provided significant financial savings. Applications that target hospitals and medical institutions include patient monitoring and transcribing notes for electronic health records (EHRs). The European Union is set to invest $24bn into artificial intelligence (AI) by 2020 in a bid to catch up with Asia and the US, who have invested heavily in AI and cloud services. This year, Google revealed its plans to harness AI and machine learning across a multitude of consumer technologies, particularly in healthcare. “If AI can shape healthcare, it has to work through the regulations of healthcare. In fact, I see that as one of the biggest areas where the benefits will play out for the next 10-20 years,” Google CEO Sundar Pichai has previously stated.
Blockchain is estimated to reach over $5.61bn by the end of 2025, even though it remains dependent on the ability to record and store information conveniently, economically and securely amongst different applications and systems. Providing transparency and eliminating third-party intermediaries, processes are streamlined, reducing healthcare costs exponentially. Unlocking the ability for providers to deliver a value-based healthcare system and enhance patient engagement, blockchain could save the industry up to $100-$150bn per year by 2025 in data breach-related costs, IT costs, operations costs, support function costs and personnel costs, according to BIS Research. Partnering with pharmaceutical giant GlaxoSmithKline (GSK), Ethereum blockchain-based supply chain platform, Viant sought to accelerate the pace of blockchain-based supply chain systems. Accenture and supply chain giant DHL have also developed a blockchain-based serialisation prototype which tracks pharmaceuticals from the point of origin to the consumer.
6. Health wearables
With the rise of lifestyle diseases, such as diabetes, more consumers are turning to health wearables that monitor glucose, heart rate, physical activity and sleep to gain a greater understanding of their health conditions. Following on from the release of the first Bluetooth headset back in 2000, the growing interest in wearables has seen monitoring our health and data become standardised. This data can be analysed by sophisticated algorithms to drive long-term diagnosis and support. Partnering with Google, health wearables company Fitbit is exploring the development of consumer and enterprise health solutions. Its acquisition of HIPAA-compliant health platform, Twine Health has seen the business enhance its clinical services by bringing on board a coaching platform, empowering people to seek better health outcomes.
- Novartis Social Business: Blending profit with purpose
- How Microsoft is transforming Canada's healthcare
- The December edition of Healthcare Global is live!
5. Electronic health records tools
From 2018-2022, the electronic health records (EHR) market is expected to grow at a compound average rate of 6% per year Providers and organisations continue to house fragmented technologies which create barriers towards collaboration and data sharing opportunities. This is further exacerbated if a patient straddles both public and private healthcare. Technology giant Apple has integrated patients’ medical records into its Health App as part of its iOS 11.3 beta. The data is encrypted and protected with the user’s iPhone passcode. Partnering with hospital providers and clinics, patients are now able to view their medical records from multiple providers within one platform. Johns Hopkins Medicine, Cedars-Sinai, Penn Medicine, UC San Diego Health and even the Cleveland Clinic have implemented this technology.
4. Healthcare transportation
Non-emergency health transportation remains a key issue worldwide, preventing patients from getting to or from a doctor’s appointment. 25% of lower-income patients have missed or rescheduled appointments due to lack of transportation, costing US health systems up to $150bn each year. Transportation companies such as Lyft and Uber have therefore entered the market by partnering with state governments to reduce these costs and deliver personalised patient care.
3. 3D Printing
Healthcare providers are set to represent the second largest industry sector in 3D manufacturing. The Food & Drug Administration’s decision to release its first comprehensive framework advising manufacturers of 3D medical products highlights its growing impact where more than 100,000 knee replacement surgeries are completed each year using 3D-printed, patient-matched surgical guides, for example. Through this process, surfaces and structures can be optimised for strength, weight and material use. Consultation between surgeons and patients has also been bolstered, where patients can better understand the complexity of his or her specific needs.
As consumers get more involved in the management of their health, consumer genetics and research companies have grown in popularity and scale. People want to further understand their genetic makeup, leading personal genomics and biotech company 23andMe to become one of the largest consumer-based organisations worldwide. Interestingly, this year, the company has entered a four-year collaboration with GSK to develop new treatments, but using human genetics as the basis for discovery.
Not only looking to develop treatments by analysing human genetics, pharmaceutical companies are looking to even remove hereditary genes which pass diseases down generations. In 2017, human embryos were successfully ‘edited’ through gene editing tool, CRISPR (Clustered, Regularly Interspaced, Short Palindromic Repeats), eradicating hypertrophic cardiomyopathy within 42 embryos.
1. Vertical integrations
As healthcare providers aim to provide greater transparency, promote collaboration and lower escalating patient costs, 2018 has been the year for a significant number of vertical integrations. CVS Health’s $68mn takeover of health insurer Aetna is a case in point. By influencing more of the supply chain, it will gain significant negotiating power to reduce costs for payers and patients, develop personalised solutions and improve overall outcomes. It will also promote the eradication of delays in process by removing any third parties within traditional business models. Other notable integrations are Optum’s acquisition of the DaVita Medical Group, Humana and Kindred Healthcare and Cigna and Express Scripts.
Reports have indicated that not only has the number of healthcare deals more than doubled in the last five years, the size of deals has also grown as a result of repeat investor interest, highlighting that this trend is here to stay.